Labeler
AstraZeneca Pharmaceuticals LP NDC Codes
AstraZeneca Pharmaceuticals LP lists 83 finished drug products in the FDA NDC Directory under NDC labeler codes 0186, 0310.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Nexium, Seroquel, Xigduo XR, Koselugo, Crestor, Lynparza, Tagrisso, Seroquel XR, Fasenra, Calquence, Pulmicort Respules, Baxfendy, Wainua, Breztri, Saphnelo
- Active ingredients
- Budesonide, Quetiapine fumarate, Dapagliflozin propanediol, Esomeprazole magnesium trihydrate, Formoterol fumarate, Metformin hydrochloride, Selumetinib, Rosuvastatin calcium, Olaparib, Osimertinib, Glycopyrrolate, Benralizumab
- NDC labeler codes
- 0186, 0310
- Strengths
- Budesonide 160 ug/1; Formoterol fumarate 4.5 ug/1; Budesonide 80 ug/1; Acalabrutinib 100 mg/1; Metformin hydrochloride 1000 mg/1; Dapagliflozin propanediol 5 mg/1; Dapagliflozin propanediol 10 mg/1; Eplontersen 45 mg/.8mL; Formoterol 4.8 ug/1; Glycopyrrolate 9 ug/1; Benralizumab 30 mg/mL; Olaparib 150 mg/1; Olaparib 100 mg/1; Osimertinib 40 mg/1; Osimertinib 80 mg/1; Pramlintide acetate 1000 ug/mL; Exenatide 250 ug/mL; Metformin hydrochloride 500 mg/1; Quetiapine fumarate 200 mg/1; Quetiapine fumarate 300 mg/1
- Dosage forms
- Tablet, Film coated, Injection, Solution, Injection, Tablet, Film coated, Extended release, Granule, Delayed release, Aerosol, Metered, Aerosol, Tablet, Tablet, Extended release, Suspension, Granule, Capsule, Powder, For suspension, Capsule, Delayed release, Injection, Powder, Lyophilized, For solution, Capsule, Gelatin coated, Tablet, Coated
- Routes
- Oral, Respiratory (Inhalation), Subcutaneous, Intravenous, Intramuscular
- Drug classes (FDA established)
- Kinase Inhibitor, Corticosteroid, Atypical Antipsychotic, beta2-Adrenergic Agonist, Sodium-Glucose Cotransporter 2 Inhibitor, Proton Pump Inhibitor, Biguanide, HMG-CoA Reductase Inhibitor, Poly(ADP-Ribose) Polymerase Inhibitor, Anticholinergic, Cholinergic Muscarinic Antagonist, Interleukin-5 Receptor alpha-directed Cytolytic Antibody, Antisense Oligonucleotide, Transthyretin-directed RNA Interaction, Type I Interferon Receptor Antagonist, CTLA-4-directed Blocking Antibody, Programmed Death Ligand-1 Blocker, P2Y12 Platelet Inhibitor, Phosphodiesterase 4 Inhibitor, Amylin Analog, GLP-1 Receptor Agonist, Estrogen Receptor Antagonist
- HCPCS / J-code
- J9173 — Injection, durvalumab, 10 mg
- Package NDCs
- 127
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Etcamahcamizestrant | Camizestrant 75 mg/1 | Tablet, Film coatedOral | 0310-0075 | 00310-0075-0100310-0075-95 | — |
| Baxfendybaxdrostat | Baxdrostat 1 mg/1 | Tablet, Film coatedOral | 0310-6001 | 00310-6001-3000310-6001-95 | — |
| Baxfendybaxdrostat | Baxdrostat 2 mg/1 | Tablet, Film coatedOral | 0310-6002 | 00310-6002-3000310-6002-95 | — |
| Wainuaeplontersen | Eplontersen 45 mg/.8mL | Injection, SolutionSubcutaneous | 0310-9420 | 00310-9420-01 | — |
| Breztribudesonide, glycopyrrolate, and formoterol fumarate | Budesonide 160 ug/1 + 2 more ingredients | Aerosol, MeteredRespiratory (Inhalation) | 0310-6616 | 00310-6616-0100310-6616-3900310-6616-95 | — |
| Saphneloanifrolumab-fnia | Anifrolumab 120 mg/.8mL | Injection, SolutionSubcutaneous | 0310-3080 | 00310-3080-0100310-3080-0200310-3080-95 | — |
| Koselugoselumetinib | Selumetinib 5 mg/1 | GranuleOral | 0310-0635 | 00310-0635-60 | — |
| Koselugoselumetinib | Selumetinib 7.5 mg/1 | GranuleOral | 0310-0640 | 00310-0640-60 | — |
| Fasenrabenralizumab | Benralizumab 10 mg/.5mL | Injection, SolutionSubcutaneous | 0310-1745 | 00310-1745-0100310-1745-95 | — |
| Wainuaeplontersen | Eplontersen 45 mg/.8mL | Injection, SolutionSubcutaneous | 0310-9400 | 00310-9400-01 | — |
| Truqapcapivasertib | Capivasertib 160 mg/1 | Tablet, Film coatedOral | 0310-9500 | 00310-9500-0100310-9500-02 | — |
| Truqapcapivasertib | Capivasertib 200 mg/1 | Tablet, Film coatedOral | 0310-9501 | 00310-9501-0100310-9501-0200310-9501-04+1 more | — |
| Airsupraalbuterol sulfate and budesonide | Albuterol sulfate 90 ug/1; Budesonide 80 ug/1 | Aerosol, MeteredRespiratory (Inhalation) | 0310-9080 | 00310-9080-1200310-9080-28 | — |
| Imjudotremelimumab | Tremelimumab 300 mg/15mL | Injection, SolutionIntravenous | 0310-4535 | 00310-4535-30 | — |
| Imjudotremelimumab | Tremelimumab 25 mg/1.25mL | Injection, SolutionIntravenous | 0310-4505 | 00310-4505-25 | — |
| Calquenceacalabrutinib | Acalabrutinib 100 mg/1 | Tablet, Film coatedOral | 0310-4513 | 00310-4513-60 | — |
| Calquenceacalabrutinib | Acalabrutinib 100 mg/1 | Tablet, Film coatedOral | 0310-3512 | 00310-3512-6000310-3512-95 | — |
| Andexxaandexanet alfa | Andexanet alfa 200 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | 0310-3200 | 00310-3200-0400310-3200-05 | — |
| Crestorrosuvastatin | Rosuvastatin calcium 5 mg/1 | Tablet, Film coatedOral | 0310-7560 | 00310-7560-90 | — |
| Crestorrosuvastatin | Rosuvastatin calcium 10 mg/1 | Tablet, Film coatedOral | 0310-7570 | 00310-7570-90 | — |
| Crestorrosuvastatin | Rosuvastatin calcium 20 mg/1 | Tablet, Film coatedOral | 0310-7580 | 00310-7580-90 | — |
| Crestorrosuvastatin | Rosuvastatin calcium 40 mg/1 | Tablet, Film coatedOral | 0310-7590 | 00310-7590-30 | — |
| Saphneloanifrolumab-fnia | Anifrolumab 300 mg/2mL | Injection, SolutionIntravenous | 0310-3040 | 00310-3040-00 | — |
| Breztribudesonide, glycopyrrolate, and formoterol fumarate | Budesonide 160 ug/1 + 2 more ingredients | Aerosol, MeteredRespiratory (Inhalation) | 0310-4616 | 00310-4616-1200310-4616-2800310-4616-39 | — |
| Koselugoselumetinib | Selumetinib 10 mg/1 | CapsuleOral | 0310-0610 | 00310-0610-2800310-0610-60 | — |
| Koselugoselumetinib | Selumetinib 25 mg/1 | CapsuleOral | 0310-0625 | 00310-0625-2800310-0625-60 | — |
| Budesonide and Formoterol Fumarate Dihydrate | Budesonide 160 ug/1; Formoterol fumarate 4.5 ug/1 | AerosolRespiratory (Inhalation) | 0310-7370 | 00310-7370-20 | — |
| Budesonide and Formoterol Fumarate Dihydrate | Budesonide 80 ug/1; Formoterol fumarate 4.5 ug/1 | AerosolRespiratory (Inhalation) | 0310-7372 | 00310-7372-20 | — |
| Fasenrabenralizumab | Benralizumab 30 mg/mL | Injection, SolutionSubcutaneous | 0310-1830 | 00310-1830-3000310-1830-85 | — |
| Lokelmasodium zirconium cyclosilicate | Sodium zirconium cyclosilicate 5 g/5g | Powder, For suspensionOral | 0310-1105 | 00310-1105-3000310-1105-39 | — |
| Lokelmasodium zirconium cyclosilicate | Sodium zirconium cyclosilicate 10 g/10g | Powder, For suspensionOral | 0310-1110 | 00310-1110-3000310-1110-3900310-1110-93 | — |
| Fasenrabenralizumab | Benralizumab 30 mg/mL | Injection, SolutionSubcutaneous | 0310-1730 | 00310-1730-3000310-1730-85 | — |
| Calquenceacalabrutinib | Acalabrutinib 100 mg/1 | Capsule, Gelatin coatedOral | 0310-0512 | — | — |
| Lynparzaolaparib | Olaparib 150 mg/1 | Tablet, Film coatedOral | 0310-0578 | 00310-0578-1200310-0578-60 | — |
| Lynparzaolaparib | Olaparib 100 mg/1 | Tablet, Film coatedOral | 0310-0668 | 00310-0668-1200310-0668-6000310-0668-95 | — |
| Lynparzaolaparib | Olaparib 150 mg/1 | Tablet, Film coatedOral | 0310-0679 | 00310-0679-1200310-0679-6000310-0679-95 | — |
| Lynparzaolaparib | Olaparib 100 mg/1 | Tablet, Film coatedOral | 0310-0569 | 00310-0569-1200310-0569-60 | — |
| Imfinzidurvalumab | Durvalumab 500 mg/10mL | Injection, SolutionIntravenous | 0310-4611 | 00310-4611-50 | J9173 |
| Imfinzidurvalumab | Durvalumab 120 mg/2.4mL | Injection, SolutionIntravenous | 0310-4500 | 00310-4500-12 | J9173 |
| Bevespi Aerosphereglycopyrrolate and formoterol fumarate | Glycopyrrolate 9 ug/1; Formoterol fumarate 4.8 ug/1 | Aerosol, MeteredRespiratory (Inhalation) | 0310-4600 | 00310-4600-12 | — |
| Tagrissoosimertinib | Osimertinib 40 mg/1 | Tablet, Film coatedOral | 0310-1248 | 00310-1248-30 | — |
| Tagrissoosimertinib | Osimertinib 80 mg/1 | Tablet, Film coatedOral | 0310-1251 | 00310-1251-30 | — |
| Tagrissoosimertinib | Osimertinib 40 mg/1 | Tablet, Film coatedOral | 0310-1349 | 00310-1349-30 | — |
| Tagrissoosimertinib | Osimertinib 80 mg/1 | Tablet, Film coatedOral | 0310-1350 | 00310-1350-3000310-1350-99 | — |
| Brilintaticagrelor | Ticagrelor 60 mg/1 | TabletOral | 0186-0776 | 00186-0776-60 | — |
| Iressagefitinib | Gefitinib 250 mg/1 | Tablet, CoatedOral | 0310-0482 | 00310-0482-30 | — |
| Daliresproflumilast | Roflumilast 250 ug/1 | TabletOral | 0310-0088 | 00310-0088-2800310-0088-39 | — |
| Daliresproflumilast | Roflumilast 500 ug/1 | TabletOral | 0310-0095 | 00310-0095-3000310-0095-90 | — |
| SymlinPenpramlintide acetate | Pramlintide acetate 1000 ug/mL | InjectionSubcutaneous | 0310-6615 | 00310-6615-02 | — |
| SymlinPenpramlintide acetate | Pramlintide acetate 1000 ug/mL | InjectionSubcutaneous | 0310-6627 | 00310-6627-02 | — |
AstraZeneca Pharmaceuticals LP: common questions
- What is AstraZeneca Pharmaceuticals LP's NDC labeler code?
- 0186, 0310. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for AstraZeneca Pharmaceuticals LP?
- Med-Code's HCPCS directory matches J9173 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.